Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Balance Sheets (Current Period Unaudited)

v3.23.1
Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 31, 2022
Current assets    
Cash and cash equivalents $ 3,355 $ 7,082
Accounts receivable 0 12
Lease receivable, current portion 15,244 15,527
Inventory 302 278
Assets held for sale 0 47
Prepaid expenses and other current assets 286 263
Total current assets 19,187 23,209
Non-current assets    
Property, plant and equipment, net 11,894 7,343
Intellectual property, net 416 461
Investment in LINICO 2,000 2,000
Other assets 463 489
Total non-current assets 14,773 10,293
Total assets 33,960 33,502
Current liabilities    
Accounts payable 770 1,075
Accrued expenses 1,508 1,780
Building purchase deposit 3,250 3,250
Lease liability, current portion 312 307
Notes payable, current portion 5,945 5,899
Total current liabilities 11,785 12,311
Non-current liabilities    
Lease liability, non-current portion 197 275
Notes payable, non-current portion 2,902 0
Total liabilities 14,884 12,586
Commitments and contingencies (see Note 13)
Stockholders’ equity    
Common stock; $0.001 par value; 200,000,000 shares authorized; 83,180,801 and 79,481,751 shares issued and outstanding as of March 31, 2023 and December 31, 2022, respectively 83 79
Additional paid-in capital 223,453 220,114
Accumulated deficit (203,883) (199,277)
Treasury stock, at cost; common shares: 510,632 and nil as of March 31, 2023 and December 31, 2022, respectively (577) 0
Total stockholders’ equity 19,076 20,916
Total liabilities and stockholders’ equity $ 33,960 $ 33,502